Key Points
- Insider buying: Orchestra BioMed insider David Hochman purchased 5,000 shares at $3.83 each, totaling $19,150. After the transaction, he owned 1,064,029 shares, a 0.47% increase in his position.
- Stock and financial snapshot: OBIO traded around $3.91 with a market cap of $234.13 million, and the company reported a smaller-than-expected quarterly loss of $0.33 per share. However, revenue came in well below analyst estimates.
- Analyst sentiment remains positive: Several firms reiterated bullish views, including buy ratings and price targets up to $20, while MarketBeat shows a consensus rating of Moderate Buy with an average target of $13.60.
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) insider David Hochman bought 5,000 shares of the business's stock in a transaction that occurred on Monday, June 1st. The shares were bought at an average cost of $3.83 per share, with a total value of $19,150.00. Following the completion of the purchase, the insider directly owned 1,064,029 shares of the company's stock, valued at $4,075,231.07. This represents a 0.47% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.
Orchestra BioMed Stock Performance
OBIO opened at $3.91 on Wednesday. The stock has a market capitalization of $234.13 million, a price-to-earnings ratio of -4.03 and a beta of 0.50. The company has a fifty day moving average of $4.18 and a 200 day moving average of $4.28. Orchestra BioMed Holdings, Inc. has a fifty-two week low of $2.20 and a fifty-two week high of $5.42. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.01 and a current ratio of 7.03.
Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.40) by $0.07. The company had revenue of $0.11 million during the quarter, compared to analysts' expectations of $0.92 million. Orchestra BioMed had a negative net margin of 166.96% and a negative return on equity of 157.46%. As a group, sell-side analysts forecast that Orchestra BioMed Holdings, Inc. will post -1.47 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
OBIO has been the subject of several research reports. HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Orchestra BioMed in a research report on Thursday, May 14th. B. Riley Financial lowered their price objective on shares of Orchestra BioMed from $12.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, May 19th. Weiss Ratings lowered shares of Orchestra BioMed from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Tuesday, April 21st. Chardan Capital reiterated a "buy" rating and set a $20.00 price objective on shares of Orchestra BioMed in a research report on Thursday, March 12th. Finally, Barclays increased their price objective on shares of Orchestra BioMed from $12.00 to $13.00 and gave the company an "overweight" rating in a research report on Wednesday, May 13th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Orchestra BioMed currently has a consensus rating of "Moderate Buy" and an average price target of $13.60.
Check Out Our Latest Stock Report on Orchestra BioMed
Hedge Funds Weigh In On Orchestra BioMed
Several institutional investors have recently bought and sold shares of OBIO. China Universal Asset Management Co. Ltd. bought a new position in Orchestra BioMed during the fourth quarter valued at $38,000. Creative Planning bought a new stake in shares of Orchestra BioMed in the 2nd quarter worth about $40,000. XTX Topco Ltd bought a new stake in shares of Orchestra BioMed in the 2nd quarter worth about $45,000. Jane Street Group LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter worth about $50,000. Finally, Virtu Financial LLC bought a new stake in shares of Orchestra BioMed in the 4th quarter worth about $57,000. Institutional investors own 53.20% of the company's stock.
Orchestra BioMed Company Profile
(
Get Free Report)
Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.
Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
